I know the public market hasn't been terribly ravenous in its voracity for venture-backed companies...but is an IPO of a venture firm the "reverse ozempic" shot to pique public appetite for our portfolio companies?

I know the public market hasn't been terribly ravenous in its voracity for venture-backed companies...but is an IPO of a venture firm the "reverse ozempic" shot to pique public appetite for our portfolio companies? 
https://www.pymnts.com/news/ipo/2025/general-catalyst-reportedly-weighing-initial-public-offering/